Stability of New Carbapenem DA-1131 to Renal Dipeptidase (Dehydropeptidase I)
AUTOR(ES)
Park, Sung Wook
FONTE
American Society for Microbiology
RESUMO
The stability of DA-1131 to renal dipeptidase (RDPase) (EC 3.4.13.19) was compared with that of imipenem and meropenem by Vmax/Km ratios as an index of the enzyme's preference for substrates. Our results showed a decreasing order of imipenem (6.24), meropenem (2.41), and DA-1131 (1.39). The biochemical evaluation of DA-1131 as the least preferred substrate of RDPase suggests its potential use as a novel β-lactam antibiotic which may be usable without coadministration of RDPase inhibitors once its clinical suitability is proven.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=127065Documentos Relacionados
- The renal membrane dipeptidase (dehydropeptidase I) inhibitor, cilastatin, inhibits the bacterial metallo-beta-lactamase enzyme CphA.
- Renal dehydropeptidase-I stability of LJC 10,627, a new carbapenem antibiotic.
- Metabolism of Thienamycin and Related Carbapenem Antibiotics by the Renal Dipeptidase, Dehydropeptidase-I
- In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I.
- In vitro and in vivo activities of LJC10,627, a new carbapenem with stability to dehydropeptidase I.